相似文献
1
Coronavirus in human diseases: Mechanisms and advances in clinical treatment.
MedComm (2020). 2020 Oct 1;1(3):270-301. doi: 10.1002/mco2.26. eCollection 2020 Dec.
2
An overview on the seven pathogenic human coronaviruses.
Rev Med Virol. 2022 Mar;32(2):e2282. doi: 10.1002/rmv.2282. Epub 2021 Aug 2.
3
The dominance of human coronavirus OC43 and NL63 infections in infants.
J Clin Virol. 2012 Feb;53(2):135-9. doi: 10.1016/j.jcv.2011.11.011. Epub 2011 Dec 19.
4
Coronaviruses - drug discovery and therapeutic options.
Nat Rev Drug Discov. 2016 May;15(5):327-47. doi: 10.1038/nrd.2015.37. Epub 2016 Feb 12.
5
Epidemiological and co-infection characteristics of common human coronaviruses in Shanghai, 2015-2020: a retrospective observational study.
Emerg Microbes Infect. 2021 Dec;10(1):1660-1668. doi: 10.1080/22221751.2021.1965498.
6
Transcriptomic profiling and genomic mutational analysis of Human coronavirus (HCoV)-229E -infected human cells.
PLoS One. 2021 Feb 25;16(2):e0247128. doi: 10.1371/journal.pone.0247128. eCollection 2021.
7
Human and novel coronavirus infections in children: a review.
Paediatr Int Child Health. 2021 Feb;41(1):36-55. doi: 10.1080/20469047.2020.1781356. Epub 2020 Jun 25.
8
Genetic variability of human coronavirus OC43-, 229E-, and NL63-like strains and their association with lower respiratory tract infections of hospitalized infants and immunocompromised patients.
J Med Virol. 2006 Jul;78(7):938-49. doi: 10.1002/jmv.20645.
9
Biology and Pathogenesis of SARS-CoV-2: Understandings for Therapeutic Developments against COVID-19.
Pathogens. 2021 Sep 19;10(9):1218. doi: 10.3390/pathogens10091218.
10
Molecular evolution of human coronavirus-NL63, -229E, -HKU1 and -OC43 in hospitalized children in China.
Front Microbiol. 2022 Nov 2;13:1023847. doi: 10.3389/fmicb.2022.1023847. eCollection 2022.
引用本文的文献
1
Pathological Sequelae of SARS-CoV-2: A Review for Clinicians.
Yale J Biol Med. 2024 Dec 19;97(4):431-445. doi: 10.59249/DQJH2274. eCollection 2024 Dec.
2
COVID-19: Recent Insight in Genomic Feature, Pathogenesis, Immunological Biomarkers, Treatment Options and Clinical Updates on SARS-CoV-2.
Curr Genomics. 2024 Apr 8;25(2):69-87. doi: 10.2174/0113892029291098240129113500.
3
Aggravated pneumonia and diabetes in SARS-CoV-2 infected diabetic mice.
Emerg Microbes Infect. 2023 Dec;12(1):2203782. doi: 10.1080/22221751.2023.2203782.
4
Tripterin liposome relieves severe acute respiratory syndrome as a potent COVID-19 treatment.
Signal Transduct Target Ther. 2022 Dec 24;7(1):399. doi: 10.1038/s41392-022-01283-6.
5
Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit stress granule formation.
PLoS Pathog. 2022 Dec 19;18(12):e1011041. doi: 10.1371/journal.ppat.1011041. eCollection 2022 Dec.
6
Diagnosis of SARS-CoV-2 during the Pandemic by Multiplex RT-rPCR hCoV Test: Future Perspectives.
Pathogens. 2022 Nov 18;11(11):1378. doi: 10.3390/pathogens11111378.
7
Immune repertoire sequencing reveals an abnormal adaptive immune system in COVID-19 survivors.
J Med Virol. 2023 Jan;95(1):e28340. doi: 10.1002/jmv.28340.
8
Indole-Based Small Molecules as Potential Therapeutic Agents for the Treatment of Fibrosis.
Front Pharmacol. 2022 Feb 16;13:845892. doi: 10.3389/fphar.2022.845892. eCollection 2022.
9
SARS-CoV-2 membrane protein causes the mitochondrial apoptosis and pulmonary edema via targeting BOK.
Cell Death Differ. 2022 Jul;29(7):1395-1408. doi: 10.1038/s41418-022-00928-x. Epub 2022 Jan 12.
10
SARS-CoV-2 spike protein harnesses SNX27-mediated endocytic recycling pathway.
MedComm (2020). 2021 Oct 8;2(4):798-809. doi: 10.1002/mco2.92. eCollection 2021 Dec.
Zotero 插件
